Litigation Details for Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. (D. Del. 2025)

Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. (D. Del. 2025)

Docket		Date Filed	2025-11-26
Court	District Court, D. Delaware	Date Terminated
Cause	35:1 Patent Infringement	Assigned To	Jennifer L. Hall
Jury Demand	None	Referred To
Parties	QILU PHARMA, INC.
Patents	11,033,495; 11,819,574; 12,144,890; 12,151,024; 12,156,940; 12,251,468; 12,296,047; 12,318,483; 12,370,142
Attorneys	Susan E. Morrison
Firms	Fish & Richardson
Link to Docket	External link to docket

Details for Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. (D. Del. 2025)

Date Filed	Document No.	Description	Snippet	Link To Document
2025-11-26				External link to document

Litigation summary and analysis for: Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. (D. Del. 2025)

Last updated: June 6, 2026

Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc., No. 1:25-cv-01445: litigation posture, likely patent-IP targets, and near-term risk to generic or product launch timelines

What does Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. (1:25-cv-01445) allege?

Answer: The case is a filed federal patent and related IP dispute between Pacira Pharmaceuticals, Inc. and The WhiteOak Group, Inc., docketed as 1:25-cv-01445 in the U.S. District Court for the District of Delaware (case number format and early filing posture consistent with Hatch-Waxman-style IP enforcement). The publicly available docket headline is insufficient to produce a precise claim chart of asserted patents or alleged infringement without the complaint text or the scheduling order.

What typically drives cases with this caption in 2025 filings?

Most Pacira enforcement filings are aimed at protecting branded injectable products (notably long-acting local anesthetic and analgesic formulations) from generic or contract-manufactured competition, commonly through one or more of these IP buckets:

• Product patents covering specific drug substance forms and finished dosage compositions
• Formulation or composition-of-matter patents covering carrier systems, stabilizers, and particle/aggregation control
• Method-of-use or patient-selection patents tied to dosing regimens and surgical/anatomic indications
• Manufacturing-process patents affecting scale-up and production critical parameters

Which product is most likely in scope?

Pacira’s enforcement patterns often center on its branded injectable platform(s). In the absence of the complaint, this case cannot be mapped to a specific NDA, Orange Book listing, or asserted patent family with the level of specificity required for litigation analysis.

What court and procedural stage is 1:25-cv-01445 in, and what does that mean for timelines?

Answer: The case number indicates a newly filed matter in 2025. With only the docket identifier provided and no entry-level events (complaint date, motions, TRO/preliminary injunction, or scheduling), the exact procedural posture cannot be determined from the input.

What you can infer from a newly docketed 2025 case

For high-stakes IP disputes, three early procedural markers usually define the trajectory:

1. Complaint filing and service
2. Rule 16 scheduling order (sets claim construction timetable, discovery start, and expert deadlines)
3. Injunction posture (if Pacira seeks immediate relief)

Without docket events (ECF document list), any specific “now/next” deadlines would be speculative.

Which patents protect Pacira products that commonly appear in Hatch-Waxman litigation?

Answer: Pacira’s patent estates in typical enforcement actions usually include composition-of-matter and formulation patents for injectable products, plus secondary patents for methods of administration and dosing regimens. The exact asserted patents in this specific case cannot be stated without the complaint or a docket document showing the asserted claims.

Typical asserted patent categories in Pacira-style disputes

• Composition/formulation: protected microparticle structure, lyophilized drug product composition, stabilizers, and reconstitution characteristics.
• Manufacturing methods: protected process parameters that reduce variability in critical quality attributes.
• Use and dosing: protected indication-specific dosing or administration technique, sometimes tied to surgical settings.

Is this case tied to Paragraph IV ANDA litigation or an Orange Book dispute?

Answer: The docket identifier alone does not establish that this is a Hatch-Waxman Paragraph IV action, as the case could be directed to:

• Non-ANDA commercial products and IP (non-Hatch-Waxman)
• ANDA, but not necessarily via Paragraph IV
• A business dispute with counterclaims that includes IP infringement theories

What evidence would confirm Paragraph IV posture?

In most Hatch-Waxman cases, the complaint and exhibits name:

• The asserted NDA and Orange Book listed patents
• The ANDA number and applicant
• The certification paragraph and FDA letter details

No such identifiers are present in the input.

What is the litigation status of Pacira v. WhiteOak, and what events matter most?

Answer: Status cannot be determined from the provided case number alone. The meaningful events for risk modeling are:

• Motion to dismiss outcomes (12(b)(6), venue/personal jurisdiction, standing)
• Claim construction schedule (Markman)
• Preliminary injunction briefing and rulings
• Patent case management developments (stipulations, narrowed asserted claims)
• Settlement filings or consent judgments

No ECF entry data is included in the input.

How strong is Pacira’s patent estate in this litigation scenario?

Answer: A strength assessment requires:

• The asserted patent numbers and independent claim structures
• File history and prosecution history (for claim scope)
• Claim construction positions and likely invalidity theories
• Prior art and obviousness landscape

None of those inputs are available in the request.

What generic entry risks exist for WhiteOak (and how do damages exposure and injunction risk typically play out)?

Answer: Without the accused product(s) and the asserted patents, entry and injunction risk cannot be mapped to a launch window or damages exposure. In general terms for U.S. patent litigation involving branded injectables, risk can break down into:

• Injunction risk: driven by likelihood of infringement and validity, irreparable harm, and balance of hardships
• Damages exposure: driven by period of infringement (including pre- and post-approval conduct) and reasonable royalty model vs lost profits
• Design-around feasibility: driven by whether protected composition/formulation claims cover the generic’s specific excipient system and microstructure

No specifics are available.

What settlement patterns are common in Pacira injectable patent disputes?

Answer: Typical settlements in branded injectable patent cases include:

• Timed launch commitments
• License grants with ongoing royalty structures
• Carve-outs for non-infringing variants and manufacturing changes
• Dismissal with prejudice and covenant-not-to-sue provisions

The input does not include any settlement terms or related docket entries.

What does the case mean for FDA regulatory approvals and labeling timelines?

Answer: FDA timelines depend on whether the litigation is linked to an ANDA litigation stay, a different regulatory pathway, or product development outside FDA exclusivity mechanisms. That linkage cannot be derived from the case number alone.

Key Takeaways

• Pacira Pharmaceuticals, Inc. v. The WhiteOak Group, Inc. is docketed as 1:25-cv-01445, but the provided input does not include complaint allegations, asserted patents, accused products, or procedural docket events.
• Litigation posture, patent scope, validity/infringement theories, and injunction or settlement risk cannot be evaluated to an actionable degree without complaint and docket text.
• For business and litigation decisioning, the next determinative documents are: the complaint (asserted patents and claim charts), the Rule 16 scheduling order (deadlines), and any claim construction briefing (Markman).

FAQs

1. What court hears Pacira v. The WhiteOak Group under 1:25-cv-01445?
   The docket identifier alone is not sufficient to state the court with certainty in this context.

2. Which asserted patents are in Pacira’s complaint for 1:25-cv-01445?
   Not identifiable from the provided input.

3. Does 1:25-cv-01445 involve an ANDA Paragraph IV certification?
   Not determinable from the provided input.

4. What deadlines usually come right after filing in federal patent cases like this?
   Rule 16 scheduling, service, early case management, and then claim construction timelines.

5. Could Pacira seek an injunction in 1:25-cv-01445?
   Injunctive relief depends on the complaint and any motion practice, which are not included in the input.

References

No sources were provided in the prompt, and no docket or complaint text is included to cite.